Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Saved in:
Bibliographic Details
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000437corr1.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850197323428134912
collection DOAJ
format Article
id doaj-art-614b9ae82a1e4906be36384ec1899554
institution OA Journals
issn 2051-1426
language English
publishDate 2020-10-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-614b9ae82a1e4906be36384ec18995542025-08-20T02:13:11ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-10-018210.1136/jitc-2019-000437corr1Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 studyhttps://jitc.bmj.com/content/8/2/e000437corr1.full
spellingShingle Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Journal for ImmunoTherapy of Cancer
title Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
title_full Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
title_fullStr Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
title_full_unstemmed Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
title_short Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
title_sort correction tislelizumab in chinese patients with advanced solid tumors an open label non comparative phase 1 2 study
url https://jitc.bmj.com/content/8/2/e000437corr1.full